论文部分内容阅读
目的 检测 CD34抗原在慢性髓系白血病 (CML)不同病期中的表达 ,并探讨其与临床化疗疗效及预后的关系。方法 采用流式细胞术检测 CML患者外周血和 (或 )骨髓单个核细胞(MNC) CD34抗原及 P1 70 糖蛋白的表达。结果 CML慢性期、加速期、急变期外周血 MNC CD34抗原阳性率比较差异有非常显著性 (P <0 .0 0 1) ,随着治疗的有效 CD34阳性率下降 ;P1 70 阴性组与 P1 70 阳性组 CD34阳性率比较差异有非常显著性 (P <0 .0 1) ,治疗有效率比较差异有差异性 (P <0 .0 5 )。结论 CML慢性期患者 CD34抗原表达与临床疗效呈负相关 ,对预测患者进入急变期有一定临床意义 ;CML病期演变时 CD34阳性白血病细胞 P1 70 的高水平表达可能是其对化疗药物具有耐药性的原因之一
Objective To detect the expression of CD34 antigen in different stages of chronic myelogenous leukemia (CML) and to explore its relationship with the efficacy and prognosis of clinical chemotherapy. Methods The expression of CD34 antigen and P170 glycoprotein in peripheral blood and / or bone marrow mononuclear cells (MNC) were detected by flow cytometry. Results The positive rate of MNC CD34 antigen in peripheral blood of chronic phase, accelerated phase and acute phase of CML was significantly different (P <0.01), and the positive rate of CD34 decreased with the treatment; the positive rate of P170 in P170 negative group The positive rate of CD34 positive rate was significantly different (P <0. 01), the treatment efficiency difference was significant (P <0. 05). Conclusion The expression of CD34 antigen in patients with chronic CML is negatively correlated with the clinical efficacy and may be of clinical significance in predicting the onset of acute phase of CML. The high level of CD70 expression in CD34 positive leukemia cells may be due to its resistance to chemotherapeutic drugs One of the reasons for sex